Similar articles for PMID: 11791124

Year	Number of Results
1883	1
1999	3
2000	2
2001	15
2002	6
2003	8
2004	8
2005	5
2006	8
2007	9
2008	6
2009	14
2010	14
2011	7
2012	4
2013	5
2014	3
2015	1
2016	1
2017	5
2018	2
2019	4
2020	10
2021	7
2022	2
2023	1
2024	0

1

Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).

Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, Tokuda Y, Watanabe T, Toi M, Hasegawa T, Osamura RY. Umemura S, et al. Breast Cancer. 2001;8(4):316-20. doi: 10.1007/BF02967531. Breast Cancer. 2001. PMID: 11791124 Review.

2

Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.

McKeage K, Perry CM. McKeage K, et al. Drugs. 2002;62(1):209-43. doi: 10.2165/00003495-200262010-00008. Drugs. 2002. PMID: 11790161 Review.

3

EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L. Gori S, et al. Ann Oncol. 2009 Apr;20(4):648-54. doi: 10.1093/annonc/mdn681. Epub 2009 Feb 2. Ann Oncol. 2009. PMID: 19188134 Free article.

4

HER2 testing recommendations in Australia.

Bilous M; HER2 Testing Advisory Board. Bilous M, et al. Pathology. 2001 Nov;33(4):425-7. doi: 10.1080/00313020120083133. Pathology. 2001. PMID: 11827407 Review.

5

Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.

Mass RD, Press MF, Anderson S, Cobleigh MA, Vogel CL, Dybdal N, Leiberman G, Slamon DJ. Mass RD, et al. Clin Breast Cancer. 2005 Aug;6(3):240-6. doi: 10.3816/CBC.2005.n.026. Clin Breast Cancer. 2005. PMID: 16137435

6

Addition of trastuzumab to chemotherapy produces 50% increase in survival in patients selected by FISH.

[No authors listed] [No authors listed] Oncology (Williston Park). 2001 Oct;15(10):1345, 1364. Oncology (Williston Park). 2001. PMID: 11702961 Free article. No abstract available.

7

HER2 overexpressing metastatic breast cancer.

Spigel DR, Burstein HJ. Spigel DR, et al. Curr Treat Options Oncol. 2002 Apr;3(2):163-74. doi: 10.1007/s11864-002-0062-8. Curr Treat Options Oncol. 2002. PMID: 12057079 Review.

8

HER2--a discussion of testing approaches in the USA.

Thor A. Thor A. Ann Oncol. 2001;12 Suppl 1:S101-7. doi: 10.1093/annonc/12.suppl_1.s101. Ann Oncol. 2001. PMID: 11521714 Free article.

9

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate.

Fornier MN, Seidman AD, Schwartz MK, Ghani F, Thiel R, Norton L, Hudis C. Fornier MN, et al. Ann Oncol. 2005 Feb;16(2):234-9. doi: 10.1093/annonc/mdi059. Ann Oncol. 2005. PMID: 15668276 Free article.

10

Compassionate use of humanized anti-HER2/neu protein, trastuzumab for metastatic breast cancer in Japan.

Tokuda Y, Suzuki Y, Ohta M, Saito Y, Kubota M, Tajima T, Umemura S, Osamura RY. Tokuda Y, et al. Breast Cancer. 2001;8(4):310-5. doi: 10.1007/BF02967530. Breast Cancer. 2001. PMID: 11791123 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

142 results

Results by year